ACLX Arcellx, Inc. Common Stock : Bullish and Bearish Analyst Opinions

Gilead (GILD) agreed to buy Arcellx (ACLX) for $7.8B. ACLX rallied 77%. This confirms that Big Pharma is actively deploying cash for pipeline acquisition. While the ACLX trade is done, it signals that small/mid-cap biotech with promising late-stage data are prime targets. WATCH. Look for other biotech names with strong clinical data in oncology/cell therapy as potential targets. M&A regulation could stifle future deals.